Hansa Biopharma to Spotlight Immunomodulatory Platform at Leerink Global Healthcare Conference

An update from Hansa Biopharma AB ( (SE:HNSA) ) is now available.

Hansa Biopharma AB, a commercial-stage biopharmaceutical company specializing in novel immunomodulatory therapies for acute and complex immune disorders, is advancing a pipeline built around its proprietary IgG-cleaving enzyme platform. Its lead asset, imlifidase, enables kidney transplantation in highly sensitized patients, while next-generation molecule HNSA-5487 is being developed for Guillain-Barré Syndrome, supporting the company’s strategy to address serious unmet needs in transplantation and autoimmune diseases.

The company announced that CEO Renée Aguiar-Lucander will take part in a fireside chat at the Leerink Global Healthcare Conference in Miami on March 9, 2026, joined on site by the COO and President U.S. and the CMO. The appearance, which will be available via webcast, underscores Hansa Biopharma’s efforts to raise its profile among global healthcare investors and stakeholders as it builds commercial momentum and expands its presence in key markets.

The most recent analyst rating on (SE:HNSA) stock is a Buy with a SEK103.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.

More about Hansa Biopharma AB

Hansa Biopharma AB is a commercial-stage biopharmaceutical company focused on developing and commercializing novel immunomodulatory therapies for acute and complex immune disorders. Leveraging a proprietary IgG-cleaving enzyme technology platform, the company targets serious unmet medical needs in transplantation, gene therapy and autoimmune diseases, with operations in Europe and the U.S. and a listing on Nasdaq Stockholm under the ticker HNSA.

Its portfolio includes imlifidase, a first-in-class IgG antibody-cleaving enzyme therapy shown to enable kidney transplantation in highly sensitized patients, and HNSA-5487, a next-generation IgG-cleaving molecule under development for Guillain-Barré Syndrome. Based in Lund, Sweden, Hansa Biopharma markets its innovations under trademarks including Hansa Biopharma, IDEFIRIX and related logos.

The company positions itself as a pioneer in immunomodulation, aiming to transform patient care in complex immune-mediated conditions through its enzyme-based approach. By pursuing indications across transplantation and autoimmune neurology, it seeks to broaden its addressable market while reinforcing its specialty focus in critical care settings.

Average Trading Volume: 512,955

Technical Sentiment Signal: Sell

Current Market Cap: SEK3.12B

See more data about HNSA stock on TipRanks’ Stock Analysis page.